Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.

Newsome SD, Krzystanek E, Selmaj KW, Dufek M, Goldstick L, Pozzilli C, Figueiredo C, Townsend B, Kletzl H, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Bhullar GD, Schneble HM, Centonze D

Open source

DOI: 10.1212/wnl.0000000000213574
Published: 2025 May 13
Container: Neurology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1212/wnl.0000000000213574,
  title = {Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.},
  author = {Newsome SD and Krzystanek E and Selmaj KW and Dufek M and Goldstick L and Pozzilli C and Figueiredo C and Townsend B and Kletzl H and Bortolami O and Zecevic D and Giacobino C and Clinch S and Shen YA and Bhullar GD and Schneble HM and Centonze D},
  year = {2025},
  journal = {Neurology},
  doi = {10.1212/wnl.0000000000213574},
  url = {https://doi.org/10.1212/wnl.0000000000213574}
}

RIS

TY  - JOUR
TI  - Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
AU  - Newsome SD
AU  - Krzystanek E
AU  - Selmaj KW
AU  - Dufek M
AU  - Goldstick L
AU  - Pozzilli C
AU  - Figueiredo C
AU  - Townsend B
AU  - Kletzl H
AU  - Bortolami O
AU  - Zecevic D
AU  - Giacobino C
AU  - Clinch S
AU  - Shen YA
AU  - Bhullar GD
AU  - Schneble HM
AU  - Centonze D
PY  - 2025
JO  - Neurology
DO  - 10.1212/wnl.0000000000213574
UR  - https://doi.org/10.1212/wnl.0000000000213574
ER  -

APA

SD, N., E, K., KW, S., M, D., L, G., C, P., C, F., B, T., H, K., O, B., D, Z., C, G., S, C., YA, S., GD, B., HM, S., & D, C. (2025). Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.. Neurology. https://doi.org/10.1212/wnl.0000000000213574

Source records

pubmed · retrieved 2026-09-27T11:07:22.750Z